Clinical Study on Ulinastatin Combined with Ambroxol in the Treatment of AECOPD Complicated with Type II Respiratory Failure
Clinical Study on Ulinastatin Combined with Ambroxol in the Treatment of AECOPD Complicated with Type II Respiratory Failure
Xia Li1*, Xueliang Zhan1 and Xinjie Shi2
ABSTRACT
The Objective of the present study was to observe and analyze the efficacy of ulinastatin combined with ambroxol in the treatment of AECOPD complicated with type II respiratory failure. A total of 180 patients treated in our hospital due to AECOPD complicated with type II respiratory failure were enrolled in the study and divided into study group and reference group, each with 90 patients. The study group was treated with ulinastatin and ambroxol, while general routine treatment was implemented in the reference group. The treatment outcomes were compared between the two groups. The blood content levels of WBC, CRP and PCT were compared between the two groups after one week of treatment. The results showed that the improvement effect was significantly superior in the study group, p<0.05. The arterial blood gas analysis showed that the arterial blood PO2 was elevated and PCO2 was decreased in the study group. The difference was statistically significant (P<0.05). It was concluded that the application of ulinastatin combined with ambroxol in the treatment of AECOPD complicated with type II respiratory failure can significantly improve the treatment effect, help patients actively improve the condition and promote body recovery as soon as possible.
To share on other social networks, click on P-share. What are these?
February
2021
Vol. 53, Iss. 1, Pages 1-400
